Lactococcus lactis D4 Decreases NF-κB and α-SMA in Rat Models of Obstructive Jaundice

Avit Suchitra, Alvarino Alvarino, Eryati Darwin, Harnavi Harun, Muhammad Iqbal Rivai, Ade Sukma

Abstract


BACKGROUND: Obstructive jaundice, often due to choledocholithiasis or malignancies, leads to immune suppression, intestinal damage, and bacterial translocation, worsening outcomes. Some inflammatory mediators like nuclear factor kappa B (NF-κB), alpha-smooth muscle actin (α-SMA), and interleukin-6 (IL-6) are important in this process. Current treatments remain inadequate, highlighting the need for novel approaches. Probiotics, such as Lactococcus lactis D4 (LLD4), may help reduce inflammation and bacterial translocation, thus offering a potential therapeutic option. This study was conducted to evaluate the effects of LLD4 on NF-κB, α-SMA, and IL-6 in obstructive jaundice rat models.

METHODS: This post-test randomized controlled study involved 15 male Wistar rats divided into three groups: sham, bile duct ligation (BDL), and BDL+LLD4 groups. The rats were maintained for 7–10 days, with the rats in BDL+LLD4 group received fermented milk containing LLD4 via gavage at a dose of 112 mg/20 gBW per day for 7 days. The expression levels of NF-κB, α-SMA, and IL-6 were analyzed using immunohistochemistry.

RESULTS: Administration of LLD4 were able to significantly reduced NF-κB expression compared to the BDL group (40.20±21.276 vs. 53.60 ± 20.403) in obstructive jaundice rat models. Though not significant, BDL+LLD4 group showed lower α-SMA expression compared to BDL group (58.40±14.271 vs. 63.20±9.16). However, administration of LLD4 did not give any significant effect on IL-6 expression.

CONCLUSION: LLD4 reduces inflammation in models of obstructive jaundice by lowering the NF-κB and α-SMA expression. This indicates that LLD4 might be potential as an adjunct therapy for reducing morbidity in obstructive jaundice cases.

KEYWORDS: obstructive jaundice, bile duct ligation, Lactococcus lactis D4, NF-κB, α-SMA, IL-6


Full Text:

PDF

References


Vagholkar K. Obstructive jaundice: Understanding the pathophysiology. Int J Surg Med. 2020; 6(4): 26-31, CrossRef.

Coucke EM, Akbar H, Kahloon A, Lopez PP. Biliary obstruction. In: StatPearls. Treasure Island: StatPearls Publishing; 2022, CrossRef.

Yao WF, Liu JW, Huang D. Preventive effect of probiotics on postoperative infection in surgical patients with obstructive jaundice. Biomed Res. 2017; 28(10): 4456-9, article.

Sarac F, Salman T, Gun F, Celik A, Gurler N, Dogru Abbasoglu S, et al. Effect of probiotic supplementation on bacterial translocation in common bile duct obstruction. Pediatr Surg Int. 2015; 31(2): 155-61, CrossRef.

Halim JAN, Lestari ES, Prasetyo SA, Muniroh M, Prasetyo AA. Combination of ursodeoxycholic acid and glutathione improves intestinal morphology in cholestasis by downregulating TNF-α expression. Indones Biomed J. 2022; 14(4): 429-35, CrossRef.

Saleena LAK, Teo MYM, How YH, In LLA, Pui LP. Immunomodulatory action of Lactococcuslactis. J Biosci Bioeng. 2023; 135(1): 1-9, CrossRef.

Pavlidis ET, Pavlidis TE. Pathophysiological consequences of obstructive jaundice and perioperative management. Hepatobiliary Pancreat Dis Int. 2018; 17(1): 17-21, CrossRef.

Gibelli NE, Tannuri U, Mello ES. Immunohistochemical studies of stellate cells in experimental cholestasis in newborn and adult rats. Clinics. 2008; 63(5): 689-94, CrossRef.

Meiliana A, Wijaya A. Gut microbiota, obesity and metabolic dysfunction. Indones Biomed J. 2011; 3(3): 150-67, CrossRef.

Ramadhan AY, Rosdiana DS. The prospect of probiotics to treat metabolic syndrome. Mol Cell Biomed Sci. 2024; 8(2): 71-80, CrossRef.

Tag CG, Sauer-Lehnen S, Weiskirchen S, Borkham-Kamphorst E, Tolba RH, Tacke F, Weiskirchen R. Bile duct ligation in mice: Induction of inflammatory liver injury and fibrosis by obstructive cholestasis. J Vis Exp. 2015; (96): 52438, CrossRef.

Suswita R, Alvarino, Darwin E, Jamsari. Lactococcus lactis D4 has potential effect to alleviate inflammation and reverse dysbiosis in colitis rat model. Indones Biomed J. 2024; 16(2): 199-207, CrossRef.

Tian X, Zhao H, Zhang Z, Guo Z, Li W. Correction: Intestinal mucosal injury induced by obstructive jaundice is associated with activation of TLR4/TRAF6/NF-κB pathways. PLoS One. 2019; 14(12): e0227310, CrossRef.

Shao C, Li Y, Chen J, Zheng L, Chen W, Peng Q, et al. Physical exercise repairs obstructive jaundice-induced damage to intestinal mucosal barrier function via H2S-mediated regulation of the HMGB1/Toll-like receptors 4/Nuclear factor kappa B pathway. Front Physiol. 2022; 12: 732780, CrossRef.

Wang J, He GZ, Wang YK, Zhu QK, Chen W, Guo T. TLR4-HMGB1-, MyD88- and TRIF-dependent signaling in mouse intestinal ischemia/reperfusion injury. World J Gastroenterol. 2015; 21(27): 8314-25, CrossRef.

Yousefi B, Eslami M, Ghasemian A, Kokhaei P, Salek Farrokhi A, Darabi N. Probiotics importance and their immunomodulatory properties. J Cell Physiol. 2019; 234(6): 8008-18, CrossRef.

Ramachandran P, Unny AK, Vij M, Safwan M, Balaji MS, Rela M. α-Smooth muscle actin expression predicts the outcome of Kasai portoenterostomy in biliary atresia. Saudi J Gastroenterol. 2019; 25(2): 101-5, CrossRef.

Liu JJ, Sun YM, Xu Y, Mei HW, Guo W, Li ZL. Pathophysiological consequences and treatment strategy of obstructive jaundice. World J Gastrointest Surg. 2023; 15(7): 1262-76, CrossRef.

Pavlidis ET, Pavlidis TE. Pathophysiological consequences of obstructive jaundice and perioperative management. Hepatobiliary Pancreat Dis Int. 2018; 17(1): 17-21, CrossRef.

Roh YS, Cho A, Cha YS, Oh SH, Lim CW, Kim B. Lactobacillus aggravates bile duct ligation-induced liver inflammation and fibrosis in mice. Toxicol Res. 2018; 34(3): 241-7, CrossRef.

Villar-Fincheira P, Sanhueza-Olivares F, Norambuena-Soto I, Cancino-Arenas N, Hernandez-Vargas F, Troncoso R, et al. Role of interleukin-6 in vascular health and disease. Front Mol Biosci. 2021; 8: 641734, CrossRef.

Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011; 1813(5): 878-88, CrossRef.

Jones C, Badger SA, Regan M, Clements BW, Diamond T, Parks RW, Taylor MA. Modulation of gut barrier function in patients with obstructive jaundice using probiotic LP299v. Eur J Gastroenterol Hepatol. 2013; 25(12): 1424-30, CrossRef.

Delgado-Venegas CS, Martínez-Hernández SL, Cervantes-García D, Montes de Oca-Luna R, de Jesús Loera-Arias M, Mata-Martínez MG, et al. Modulating effects of the probiotic Lactococcus lactis on the hepatic fibrotic process induced by CCl4 in Wistar rats. Exp Ther Med. 2021; 21(4): 339, CrossRef.

Jastrząb R, Tomecki R, Jurkiewicz A, Graczyk D, Szczepankowska AK, Mytych J, et al. The strain-dependent cytostatic activity of Lactococcus lactis on CRC cell lines is mediated through the release of arginine deiminase. Microb Cell Fact. 2024; 23(1): 82, CrossRef.

Su ACY, Ding X, Lau HCH, Kang X, Li Q, Wang X, et al. Lactococcus lactis HkyuLL 10 suppresses colorectal tumourigenesis and restores gut microbiota through its generated alpha-mannosidase. Gut. 2024; 73(9): 1478-88, CrossRef.




DOI: https://doi.org/10.18585/inabj.v16i6.3384

Copyright (c) 2024 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

Indexed by:

                  

               

                

 

 

The Prodia Education and Research Institute